A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

NCT00382213 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: Olmesartan medoxomil
DRUG: Placebo

Sponsor

Daiichi Sankyo